Riskpilot← Back to searchSign inGet full accessEmbreis AB
ABActiveOrg 5567532857Tumstocksvägen 11 BWholesale of pharmaceutical and medical goods · NACE 4646Est. 200810 employees
Revenue 2024
SEK 46,2M
+4% vs 2023
EBITDA margin
6.3%
-8% vs 2023
Equity ratio
40.0%
Financial strength
Net profit 2024
SEK 2M
-10% vs 2023
| Revenue | SEK 46,2M | +4% |
| EBITDA | SEK 2,9M | -8% |
| Net profit | SEK 2M | -10% |
| Total assets | SEK 13,5M | -2% |
| Equity | SEK 5,4M | -1% |
| Employees | 10 | — |
Legal name
Embreis AB
Org number
5567532857
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
4 mars 2008
Share capital
SEK 100 000
Employees
10 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna
Company purpose
Bolaget skall bedriva import och försäljning av ortopediska och ortopedtekniska hjälpmedel samt därmed förenlig verksamhet.
Address
Tumstocksvägen 11 B
Phone
+46841062100
Email
thomas.hammarlund@embreis.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 27 410 | 30 526 | 29 064 | 32 070 | 40 274 | 44 233 | 46 188 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | 605 | 444 | 1 325 | 2 327 | 490 | 2 260 | 2 648 | 2 729 | 3 181 | 2 917 |
| Depreciation & amort. | — | — | −107 | −134 | −180 | −158 | −161 | −245 | −250 | −258 |
| EBIT | 605 | 444 | 1 218 | 2 193 | 310 | 2 102 | 2 487 | 2 484 | 2 931 | 2 659 |
| Net financials | 48 | −66 | −51 | −50 | −47 | −74 | −33 | −40 | −51 | −54 |
| Profit before tax | 653 | 578 | 834 | 2 476 | 263 | 2 028 | 2 454 | 2 444 | 2 881 | 2 604 |
| Tax | −158 | −146 | −220 | −579 | −82 | −450 | −530 | −541 | −638 | −585 |
| Net profit | 495 | 432 | 614 | 1 897 | 181 | 1 578 | 1 924 | 1 903 | 2 243 | 2 019 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 5 344 | 5 777 | 6 748 | 8 469 | 8 586 | 10 201 | 11 685 | 12 379 | 13 788 | 13 453 |
| Equity | 1 138 | 1 171 | 1 384 | 2 881 | 282 | 3 349 | 4 340 | 4 670 | 5 428 | 5 385 |
| Long-term debt | 600 | 600 | 600 | 480 | 280 | 80 | 0 | 0 | 0 | 0 |
| Short-term debt | 3 406 | 4 006 | 4 430 | 5 108 | 8 024 | 6 773 | 7 345 | 7 709 | 8 360 | 8 068 |
| Total debt | 4 006 | 4 606 | 5 030 | 5 588 | 8 304 | 6 853 | 7 345 | 7 709 | 8 360 | 8 068 |
EBITDA margin
6.3%
This company
15.8%
Market median
-60% vs market
20152024
Equity ratio
40.0%
This company
38.2%
Market median
+5% vs market
20152024
Return on equity
37.5%
This company
18.4%
Market median
+104% vs market
20152024
Net profit margin
4.4%
This company
8.1%
Market median
-46% vs market
20152024
Asset turnover
3.43×
This company
1.12×
Market median
+206% vs market
20152024
Debt / equity
1.50×
This company
0.62×
Market median
-142% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
HT Audit | Audit | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Chairman | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Embreis AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hans Thomas Kullman | Audit | 0 companies |
| Jan Edvard Marcus Randström | Board of Directors | 0 companies |
| Ulf Göran Odenblad | Board of Directors | 0 companies |
| Kent Ronny Hammarlund Weiderstål | Deputy Board Member | 0 companies |
| Thomas Hammarlund | Chairman | 0 companies |